There are currently 140 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
NCT04821271
Recruiting
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly. Objective: To see if TS-161 will improve symptoms of depression in people with MDD. Eligibility: Adults ages 18-65 with MDD without psychotic features. Design: Participants will be screened under a separate protocol. They will have blood tests. They will complete surveys about their sympto... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder, Treatment-Resistant Depression, Depression
Register for Updates
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
NCT04855747
Recruiting
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2024
Locations: Relmada Site, Saraland, Alabama +77 locations
Conditions: Major Depressive Disorder, Depression
Register for Updates
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
NCT06011577
Recruiting
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2024
Locations: Relmada Site, Dothan, Alabama +42 locations
Conditions: Major Depressive Disorder, Depression
Register for Updates
Open Label Optimization Study
NCT05819021
Recruiting
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I at the end of the treatment Participants will receive 10 treatments per day for 5 days (M-F) of SAINT®
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: BrainHealth Solutions, Costa Mesa, California +6 locations
Conditions: Major Depressive Disorder
Register for Updates
XEN1101 for Major Depressive Disorder
NCT04827901
Recruiting
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York +1 locations
Conditions: Major Depressive Disorder
Register for Updates
Neural Circuit Effects of Ketamine in Depression
NCT06213324
Recruiting
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Major Depressive Disorder
Register for Updates
Comparing Individual Therapies for Veterans With Depression, PTSD, and Panic Disorder
NCT04293341
Recruiting
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders. However, CBT is largely underutilized within the Department of Veterans Affairs due to the cost and burden of trainings necessary to deliver all of the related disorder-specific treatments (DSTs). Transdiagnostic Behavior Therapy (TBT), in contrast, is specifically designed to address numerous distinct disorders within a single protocol in Veterans with depressive/... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/12/2024
Locations: Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina
Conditions: Major Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder and Agoraphobia
Register for Updates
Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.
NCT03265808
Recruiting
The purpose of this study is to look at the safety of a study treatment with stem cells in Alcohol Use Disorder And Major Depression (AUD-MD) subjects.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/08/2024
Locations: University of Texas Rio Grande Valley School of Medicine, Harlingen, Texas
Conditions: Major Depressive Disorder, Alcohol Use Disorder
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
02/06/2024
Locations: Site 200, Phoenix, Arizona +34 locations
Conditions: Major Depressive Disorder
Register for Updates
Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses
NCT04276259
Recruiting
The central goal of this application is to demonstrate the causal contribution of reward learning signals (expected values and reward prediction errors [RPE]) to antidepressant responses (Aim1) by experimentally manipulating expected values using transcranial magnetic stimulation (TMS) targeting the vmPFC (Aim 2) and μ-opioid striatal RPE signal using pharmacological approaches (Aim 3).
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/05/2024
Locations: Bellefield Tower, Pittsburgh, Pennsylvania
Conditions: Major Depressive Disorder, Depression
Register for Updates
Individualized Targeting and Neuromodulation of Late-Life Depression
NCT04543773
Recruiting
An open-label, single-arm, clinical research study about how to make transcranial magnetic stimulation (TMS), an FDA-approved treatment, more effective for patients with late-life depression using fMRI.
Gender:
All
Ages:
Between 60 years and 79 years
Trial Updated:
02/05/2024
Locations: University of New Mexico HSC, Albuquerque, New Mexico
Conditions: Major Depressive Disorder
Register for Updates
Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
NCT04973930
Recruiting
Cancer and depression commonly occur together, and each worsens the other. We conducted a large psychotherapy study treating depression in breast cancer patients, showing that psychotherapy lowers symptoms. Surprisingly, no studies have compared depression-focused psychotherapy to antidepressant medication for patients with breast cancer and depression. We applied to the National Cancer Institute for a large, cross-national grant. Reviewers asked us to first demonstrate that patients would accep... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/01/2024
Locations: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York
Conditions: Major Depressive Disorder, Breast Cancer, Venlafaxine
Register for Updates